In conclusion, our findings further support the role of neoadjuvant chemoimmunotherapy before NSCLC resection and expand on the standard-of-care neoadjuvant Nivo+CT by incorporating CTLA-4 blockade to this treatment regimen. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.